L ynch syndrome (LS) is an autosomal dominant cancer-predisposing syndrome caused by germline mutations in one of the DNA mismatch repair (MMR) genes (MLH1, MSH2, MSH6, PMS2) or within the epithelial adhesion molecule (EPCAM) gene adjacent to the MSH2 gene (1) . An additional somatic event in the wild-type allele is necessary to inactivate both MMR gene copies. Defective MMR proteins result in an inability to repair mismatched bases in DNA sequences. The tumors show microsatellite instability (MSI), which reflects an increased rate of mutations, primarily insertions/deletions in short DNA repeats (2) . The syndrome has a high penetrance, with a 70% to 90% lifetime risk for cancer in mutation carriers (3); for details, see the Prospective Lynch Syndrome Database by InSiGHT (http://lscarisk.org). Colorectal cancer is the most common tumor type, followed by endometrial cancer in women. Patients with LS are at risk for a wide spectrum of other tumors, including ovarian, urinary tract, small bowel, gastric, hepatobiliary, and malignant brain tumors. Recently, a neuroendocrine tumor, adrenal carcinoma, was reported to be part of the syndrome (4). The occurrence of pituitary tumors in LS has not been previously addressed.
Case
A 51-year-old man presented with Cushing syndrome, marked hypokalemia (1.9 to 2.2 mmol/L), urinary free cortisol 53 times above the upper limit of normal, and padrenocorticotropic hormone (ACTH) 68 to 72 (reference ,10 pmol/L). The patient belonged to a family with LS and was shown to carry the familial mutation c.1587delA (p.Glu530Lysfs) in MSH2 by blood sampling. One of his first-degree relatives had colon carcinoma. The patient had been operated on for colon carcinoma at the age of 39 years. Magnetic resonance imaging showed a pituitary tumor eroding the floor of the sella and extending into the sphenoidal sinus [ Fig. 1(a) ]. Pituitary surgery was performed. The tumor tissue was positive for ACTH, had high mitotic numbers and atypical nuclei, had a Ki-67 of 40%, and was p53 positive in most cells.
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F-FDG positron emission tomography/computed tomography scan of the thorax and abdomen did not show any metastases. After surgery, ACTH transiently decreased to 11 pmol/L and s-cortisol to 42 nmol/L. Subsequently, the patient had another pituitary surgery, fractionated radiotherapy with 50 Gy, and bilateral adrenalectomy because of hypercortisolism not controlled by ketoconazole and metyrapone. After the bilateral adrenalectomy, ACTH remained below 100 pmol/L for 10 months and then rapidly increased to 43,000 pmol/L with liver enzymes elevated. Computed tomography scan showed multiple liver metastases [ Fig. 1(b) ], and a biopsy confirmed a pituitary origin. After five cycles of temozolomide, computed tomography showed $50% regression of the liver metastases, and p-ACTH gradually decreased to a nadir of 5075 pmol/L. After 6 months on temozolomide, there was a progression of the liver metastases and spread to the skeleton. Addition of capecitabine did not arrest the course. The patient died 2 years after diagnosis of the pituitary tumor.
Analyses of MMR and MSI were performed on paraffin-embedded tumor removed at the first surgery; for methods, see Joost et al. (5) . The protein expression of MLH1, MSH2, MSH6, and PMS2 in neoplastic cells was classified as retained (presence of nuclear staining), lost, or reduced. Instability for one of five markers was classified as MSI low, instability for $2 as MSI high, and stability for all markers as microsatellite stable. The tumor of the patient showed unambiguous loss of MSH2 and MSH6 ( Fig. 2 ) with retention of MLH1 and PMS2 consistent with the patient's germline mutation and was MSI low.
Nationwide Study
The study population was recruited from the LS registries in Sweden (University Hospitals Lund/Malmö, Linköping, Gothenburg, Stockholm, Uppsala, Umeå). These registries, which include all families with a confirmed germline MMR mutation, were initiated between 1990 and 2004. With use of the unique personal identification number in 
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Pituitary Disease in the Nationwide LS Cohort
In total, 910 (426 men and 484 women) unique individuals with an LS-associated mutation were found (MLH1, 39.1%; MLH1/MSH2, 0.1%; MLH1/PMS2, 0.7%; MSH2, 29.8%; MSH2/MSH6, 0.2%; MSH6, 22.1%; PMS2, 7.5%; EPCAM, 0.1%; and EPCAM/MSH2, 0.4%). Age at end of study (December 2015) or age at death ranged from 19 to 96 years (median, 54 years). In total, 114 persons were deceased (median age, 69 years; range, 21 to 92 years).
The study identified five cases with pituitary disease. Two did not have a pituitary tumor; one had panhypopituitarism after surgery for an anaplastic astrocytoma, and one was diagnosed with growth hormone deficiency during childhood and developed complete hypopituitarism in adolescence. Imaging showed empty sella.
Three patients with LS had a clinically relevant pituitary tumor (Table 1) . For case 1, see previous text. Case 2, a woman with a MSH6 germline mutation (c.2062_2063delGT), had a microprolactinoma diagnosed at age 39 years during investigation of infertility and galactorrhea. She was treated with dopamine agonists; prolactin normalized, and the tumor partially regressed. At age 49 years, she was diagnosed with endometrial carcinoma. Other tumors among her first-degree relatives included prostate cancer and a colon polyp. Case 3, a man with a PMS2 mutation (c.2113C.A), developed visual disturbances at age 44 years due to an invasive, nonsecreting Fig. 1(c) ]. At transsphenoidal surgery, tumor tissue was by mistake not sent for histopathology. At age 52 years, he was diagnosed with colon carcinoma. One of his first-degree relatives had colon carcinoma.
Discussion
To our knowledge, this case is the first description of a pituitary tumor in a patient with LS. In addition to the patient's inherited MSH2 mutation, the tumor displayed MSI, a typical feature of MMR deficiency resulting from functional inactivation of both MSH2 alleles. At diagnosis, there were no detectable metastases; 16 months later, there was a widespread dissemination to the liver. Considering that the average lag time from diagnosis to metastases is 6.6 years in pituitary carcinomas (6) , this course was rapid.
The combination of LS and an aggressive pituitary tumor made us investigate the occurrence of pituitary tumors in a national cohort of LS. Among 910 patients with LS, two additional pituitary tumors were found: another large invasive adenoma and a microprolactinoma diagnosed in the workup of infertility and galactorrhea. The reported prevalence of pituitary tumors in the general population in western Europe is~1: 1000, 0.94:1000 in Belgium (7), and 1.15:1000 in Iceland (8) . Thus, three clinically relevant pituitary tumors in the LS cohort of 910 subjects is more than expected. Around 5% of pituitary tumors occur in a familial setting, including FIPA (AIP), MEN1 (MEN1), MEN4 (CDKN1B), Carney complex (PRKAR1A), DICER1, and SDHx mutations (9) . Hereditary tumors seem to occur at an earlier age and be more aggressive than sporadic pituitary tumors (9) .
MSI, the phenotypic consequence of MMR deficiency, seems rare in benign pituitary adenomas and was reported in none of 100 (10) and in 1 of 31 adenomas (11), respectively. In apparently sporadic aggressive pituitary tumors and carcinomas, MSH6 deficiency was reported in 4 of 13 patients; expression of other MMR proteins was not assessed (12) . Intact MMRs were found in two other studies in a total of 23 patients with sporadic aggressive pituitary tumors (13, 14) . Notably, loss of MSH6 was observed during transformation of an atypical prolactinoma into a pituitary carcinoma (15) . This supports that MMR gene mutations could contribute to the development of aggressive pituitary tumors.
MMR-deficient tumors express an abundance of mutated proteins and harbor infiltrating cytotoxic T cells (16) . In this context, MMR-deficient tumors of various types were recently shown to be susceptible to treatment with a programmed death 1 pathway-blocking antibody. An objective response was seen in 4 of 10 patients with progressive metastatic disease upon treatment with pembrolizumab vs. in none of 18 patients with intact MMRs (17) .
Conclusion
The present findings indicate that mutations in MMR genes could predispose to the development of pituitary tumors. Of particular interest was that two of the three identified patients had invasive large tumors, of which one rapidly evolved into a carcinoma. Notably, in two of the affected patients, the pituitary tumor was the first manifestation of LS. Endocrinologists should be aware of the possibility of MMR deficiency in aggressive pituitary tumors, especially because these tumors may benefit from treatment with programmed death 1 blockade. Our findings also suggest that surveillance for pituitary tumors should be considered in LS mutation carriers. Furthermore, in the workup of patients with aggressive pituitary tumors, we propose that a family history of solid tumors typical for LS, especially colon and endometrial cancer, should be asked for. 
